Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | VAL-083 |
| Synonyms | |
| Therapy Description |
Dianhydrogalactitol (VAL-083) is a DNA cross-linking agent which has shown anti-tumor activities in clinical settings (Journal of Clinical Oncology 36, no. 15_suppl., PMID: 6784907). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| VAL-083 | Dianhydrogalactitol|VAL083|VAL 083 | Dianhydrogalactitol (VAL-083) is a DNA cross-linking agent which has shown anti-tumor activities in clinical settings (Journal of Clinical Oncology 36, no. 15_suppl., PMID: 6784907). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01478178 | Phase Ib/II | VAL-083 | Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma or Progressive Secondary Brain Tumor | Completed | USA | 0 |
| NCT03970447 | Phase II | VAL-083 ADI-PEG 20 AZD1390 VT1021 Lomustine Regorafenib Temozolomide GDC-0084 | A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE) | Recruiting | USA | FRA | DEU | CHE | CAN | AUS | 0 |
| NCT02717962 | Phase II | VAL-083 | Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma | Completed | USA | 0 |